Loading grant details…
Personalized Adjuvant Treatment for HR+/HER2- breast cancer FOR YOUNG patients
| Funder | European Commission |
|---|---|
| Recipient Organization | Unicancer |
| Country | France |
| Start Date | Jan 01, 2025 |
| End Date | Dec 31, 2031 |
| Duration | 2,555 days |
| Number of Grantees | 27 |
| Roles | Associated Partner; Participant; Coordinator; Third Party |
| Data Source | European Commission |
| Grant ID | 101156800 |
Grant Description
Worldwide, ~7 million women live with or beyond Breast Cancer (BC), as 10-year survival rates exceeding 80% for early-stage (I-III) BC. Premenopausal BC accounts for 25% in the EU and 55% in low/middle income countries.
Most premenopausal women with BC have high risk of recurrence, therefore standard treatment includes adjuvant chemo- (CT) and endocrine therapy (ET).
However, treatment has substantial physical, emotional and social burden, which is often more pressing for younger compared to older patients.Gene-expression assays are used for post-menopausal patients to identify women who can safely forego CT without detriment on clinical outcomes, preserving Quality of Life (QOL).
However, a definitive study has yet to be conducted among premenopausal women with high-risk HR+HER2-BC.
The primary objective of PATH-FOR-YOUNG is to conduct a pragmatic randomized controlled trial (RCT) with 5000 patients validating the use of a gene-expression assay to drive adjuvant treatment decisions in this target population.PATH-FOR-YOUNG aims to achieve its objective in 7-years.
The project (i) builds on and complements an ongoing twin RCT to ensure timely recruitment, (ii) leverages on a large international consortium of oncologists, pathologists, patient representatives, psychologists, sociologists, ethics and communication experts, biostatisticians, health economists, and technology providers, to assure complementary and multidisciplinary expertise, and (iii) highlights patient-engagement, participatory care, and early involvement of end users.
PATH-FOR-YOUNG will also study implementation of digital self-management to support patients throughout the cancer journey and particularly while on ET to improve QOL and medication adherence.
A full HTA will ensure a path towards cross-country implementation.PATH-FOR-YOUNG has the ambition to improve BC care, fully integrating the predictive, personalized, preventive, and participatory principles of health management.
All Grantees
Latin American Cooperative Oncology Group; Institut Gustave Roussy; Stichting Eupati Foundation; Unicancer; Breast International Group, B.I.G.Aisbl; Instituto D'Or de Pesquisa E Ensino; Grupo de Estudios Clinicos Oncologico Peruano Gecoperu; Assistance Publique Hopitaux de Paris; Gr Espanol de Estudio Y Tratamientode Intensific. Y Otras Estrateg.Experiment. En Tumores Solidos - Grupo Solti; Cancer Trials Ireland Company Limited By Guarantee; Europa Donna Slovensko Zdruzenje Za Boj Proti Raku Dojk; Universita Degli Studi Di Torino; Dana-Farber Cancer Institute Inc; Clinical Research Technology Srl; Klineo; Resilience; Elliniki Synergazomeni Ogkologiki Omada; The University of Sydney; Innovandum Health Sl; Grupo Argentino de Investigacion Clinica En Oncologia Asociacion Civil; Anz Breast Cancer Trials Group Ltd; Universidad de Castilla - la Mancha; Gruppo Oncologico Italiano Di Ricerca Clinica; Europa Donna the European Breast Cancer Coalition; University of Warwick; Central and East European Oncology Group; Association Hospitaliere de Bruxelles-Centre Hospitalier Universitaire Jules Bordet
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
